New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
08:14 EDTMRK, NVSNovartis, Merck in talks to trade different businesses, Bloomberg reports
Novartis (NVS) and Merck (MRK) are in talks to trade its animal-health and human vaccines businesses for the New Jersey drugmaker’s over-the-counter health-products unit, sources say, reports Bloomberg. The swap would fit strategies at both companies to focus on core strengths.The two drugmakers may each trade about $5B in assets to do so, sources say.Reference Link
News For NVS;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2015
07:04 EDTMRKMerck narrows FY15 EPS view to $3.45-$3.55, consensus $3.45
Subscribe for More Information
07:03 EDTMRKMerck reports Q2 EPS 86c, consensus 81c
Reports Q2 revenue $9.8B, consensus $9.8B.
06:49 EDTMRKMerck to acquire cCam Biotherapeutics for $95M
Merck and cCAM Biotherapeutics announced that the companies have signed a definitive agreement under which Merck will acquire cCAM Biotherapeutics, a privately held biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding stock of cCAM in exchange for an upfront payment of $95M in cash. In addition, cCAM shareholders of record are eligible to receive a total of up to $510M associated with the attainment of certain clinical development, regulatory and commercial milestones. The transaction is subject to certain closing conditions.
06:32 EDTMRKMerck's grazoprevir/elbasvir application accepted by FDA
Subscribe for More Information
July 27, 2015
15:03 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:43 EDTMRKEarnings Watch: Merck's Keytruda sales will be focus in Q2 results
Subscribe for More Information
08:32 EDTMRKMerck receives 'positive' CHMP opinion for Zerbaxa
Subscribe for More Information
07:37 EDTMRKAeterna Zentaris starts promoting Saizen for injection in 25 U.S. territories
Subscribe for More Information
July 24, 2015
10:56 EDTNVSNovartis announces FDA approval of Odomzo
Subscribe for More Information
09:02 EDTNVSLigand says Revolade recommended by CHMP for EU approval for SAA
Subscribe for More Information
07:17 EDTNVSNovartis combination therapy Tafinlar, Mekinist achieves regulatory milestones
Subscribe for More Information
July 23, 2015
11:04 EDTMRKMerck announces EMA acceptance of MAA for grazoprevir/elbasvir
Subscribe for More Information
July 22, 2015
07:04 EDTMRKMerck's Keytruda approved by EU for treatment of advanced melanoma in adults
Merck announced that the European Commission has approved KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of advanced melanoma in adults. The European Commission approval of pembrolizumab is based on data from three clinical studies conducted in more than 1,500 first-line and previously-treated patients with advanced melanoma. Pembrolizumab received European Commission regulatory approval based on Phase 3 data which showed it is the first and only anti-PD-1 therapy to provide a statistically superior survival benefit as a monotherapy compared to ipilimumab, the current standard of care for advanced melanoma. Today’s approval allows marketing of pembrolizumab in all 28 EU member states at the approved dose of 2 mg/kg every three weeks. The European Commission’s approval is based on data from three studies -- KEYNOTE-001, KEYNOTE-002 and KEYNOTE-006. These studies evaluated the efficacy and safety of pembrolizumab in advanced melanoma patients – across treatment lines, prognostic factors, tumor characteristics, and BRAF mutational status – and established 2 mg/kg every three weeks as the approved dose.
07:03 EDTNVSIgnyta names Bernard Parker as Chief Commercial Officer
Subscribe for More Information
06:05 EDTMRKMerck, Ablynx expand immuno-oncology collaboration
Subscribe for More Information
July 21, 2015
11:49 EDTNVSNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
05:20 EDTNVSNovartis backs FY15 revenue guidance of up mid-single digit
Subscribe for More Information
05:17 EDTNVSNovartis reports Q2 core EPS $1.27, consensus $1.24
Reports Q2 revenue $12.7B, consensus $12.44B. Further strengthening of USD impacted sales by -11% and core operating income by -13%. Growth Products, an indicator of the rejuvenation of the portfolio, contributed 35% of continuing operations net sales in Q2, and were up 24%. In Pharmaceuticals, Growth Products contributed 44% of division net sales in the quarter, and sales for these products were up 38%.
July 20, 2015
08:25 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:32 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use